Abstract
Purpose
The purpose of our study was to evaluate the efficacy of percutaneous sclerotherapy using bleomycin in treatment of lymphatic malformations.
Methods
Between January 2009 and January 2013, ten patients with lymphatic malformations who were admitted to the interventional radiology department were included in this retrospective study. Intralesional bleomycin was administered by percutaneous injection through 21–23 Gauge needles with a dose of 1 mg/kg body weight. Patients were clinically and radiologically assessed at baseline and followed at first and third months after treatment. Response to treatment was measured visually by using photographs and by radiological images. Symptomatic improvement was also evaluated either by patients or parents.
Results
Excellent resolution was obtained visually in 80% of patients with lymphatic malformation. Significant resolution was achieved in 20% of patients. The percentage of radiographic resolution in size and the improvement in symptoms evaluated by patients or parents were similar with visual outcomes. No side effects were recorded except for fever in one patient and transient erythema in another patient.
Conclusion
Intralesional bleomycin is a safe and effective treatment for patients with lymphatic malformations.
Similar content being viewed by others
References
Enjolras O, Mulliken JB. Vascular tumors and vascular malformations [new issues]. Adv Dermatol. 1997;13:375–423.
Villavicencio JL, Scultetus A, Lee BB. Congenital vascular malformations: when and how to treat them. Semin Vasc Surg. 2002;15:65–71.
Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg. 1982;69:412–22.
Molitch HI, Unger EC, Witte CL, et al. Percutaneous sclerotherapy of lymphangioma. Radiology. 1995;194:343–7.
Dubois J, Garel L. Practical aspect of intervention in vascular anomalies in children. Semin Intervent Radiol. 2002;19:73–82.
Al-Salem AH. Lymphangiomas in infancy and childhood. Saudi Med J. 2004;25(4):466–9.
Giguere CM, Bauman NM, Smith RJ. New treatment options for lymphangioma in infants and children. Ann Otol Rhinol Laryngol. 2002;111:1066–75.
Alqahtani A, Nguyen LT, Flageole H, Shaw K, Laberge JM. 25 years’ experience with lymphangiomas in children. J Pediatr Surg. 1999;34:1164–8.
Mathur N, Rana I, Bothra R, Dhawan R, Kathuria G, Pradhan T. Bleomycin sclerotherapy in congenital lymphatic and vascular malformations of head and neck. Int J Pediatr Otorhinolaryngol. 2005;69:75–80.
Sacks D, et al. Society of interventional radiology clinical practice guidelines. J Vasc Interv Radiol. 2003;14(9):S199–202.
Shiels WE, Kenny BD, Caniano DA, et al. Definitive percutaneous treatment of lympathic malformations of the trunk and extremities. J Pediatr Surg. 2008;43:136–40.
Zhong PQ, Zhi FX, Li R, Xue JL, Shu GY. Long-term results of intratumorous bleomycin-A5 injection for head and neck lymphangioma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998;86:139–44.
Green D. Mechanism of action of sclerotherapy. Semin Dermatol. 1993;12:88–97.
Nehra D, Jacobson L, Barnes P, Mallory B, Albanese CT, Sylvester KG. Doxycycline sclerotherapy as primary treatment of head and neck lymphatic malformations in children. J Pediatr Surg. 2008;43:451–60.
Cahill AM, Nijs E, Ballah D, et al. Percutaneous sclerotherapy in neonatal and infant head and neck lymphatic malformations: a single center experience. J Pediatr Surg. 2011;46:2083–95.
Peters DA, Courtemanche DJ, Heran MK, Ludeman JP, Prendiville JS. Treatment of cystic lymphatic vascular malformation with OK-432 Sclerotherapy. Plast Reconstr Surg. 2006;118:1441–6.
Etensel B, Özkısacık S, Temir G, Karkıner A, Edirne Y, Yazıcı M, Karaca İ, Gürsoy H. Çocuklarda lenfanjiom tedavisinde OK-432 kullanımı sonuçlarımız. ADÜ Tıp Fakültesi Dergisi. 2006;7:31–4.
Shergill A, John P, Amaral JG. Doxycycline sclerotherapy in children with lymphatic malformations: outcomes, complications and clinical efficacy. Pediatr Radiol. 2012;42:1080–8.
Alomari AI, Karian VE, Lord DJ, et al. Percutaneous sclerotherapy for lymphatic malformations: a retrospective analysis of patient-evaluated improvement. J Vasc Interv Radiol. 2006;17:1639–48.
Burrows PE, Mitri RK, Alomari A, et al. Percutaneous sclerotherapy of lymphatic malformations with doxycycline. Lymphat Res Biol. 2008;6:209–16.
Chaudry G, Guevara CJ, Rialon KL, Kerr C, Mulliken JB, Greene AK, Alomari AI. Safety and efficacy of bleomycin sclerotherapy for microcystic lymphatic malformation. Cardiovasc Interv Radiol. 2014;37:1476–81.
Acord M, Srinivasan AS, Cahill AM. Percutaneous treatment of lymphatic malformations. Tech Vasc Interv Radiol. 2016;19:305–11.
Umezawa H. Recent study on biochemistry and action of Bleomycin. In: Carter SK, Crook ST, Umezawa H, editors. Bleomycin: current status and new developments. New York: Academic Press; 1978. p. 15–20.
Yura J, Hashimoto T, Tsuruga N, Shibata K. Bleomycin treatment for cystic hygroma in children. Nippon Geka Hokan. 1977;46:607–14.
Şanlıalp I, Karnak I, Tanyel FC, Şenocak ME, Büyükpamukçu N. Sclerotherapy for lymphangioma in children. Int J Pediatr Otorhinolaryngol. 2003;67:795–800.
Saddal NS, Sharif A, Ahmad S, et al. Intralesional bleomycin injection: a primary therapy for peripheral lymphangiomas. Pak J Med Sci. 2007;23:220–2.
Acevedo JL, Shah RK, Brietzke SE. Nonsurgical therapies for lymphangiomas: a systematic review. Otolaryngol Head Neck Surg. 2008;138:418–24.
Sainsbury DC, Kessell G, Fall AJ, Hampton FJ, Guhan A, Muir T. Intralesional bleomycin injection treatment for vascular birthmarks: a 5-year experience at a single United Kingdom unit. Plast Reconstr Surg. 2011;127:2031–44.
Niramis R, Watanatittan S, Rattanasuwan T. Treatment of cystic hygroma by intralesional bleomycin injection: experience in 70 patients. Eur J Pediatr Surg. 2010;20:178–82.
MacIntosh PW, Yoon MK, Fay A. Complications of intralesional bleomycin in the treatment of orbital lymphatic malformations. Semin Ophthalmol. 2014;29:450–5.
Horbach SE, Rigter IM, Smitt JHS, Reekers JA, Spuls PI, van der Horst CM. Intralesional bleomycin injections for vascular malformations: a systematic review and meta-analysis. Plast Reconstr Surg. 2016;137:244–56.
Ionescu G, Mabeta P, Dippenaar N, Muir T, Fourie P, Shelver G. Bleomycin plasma spill-over levels in paediatric patients undergoing intralesional injection for the treatment of haemangiomas. S Afr Med J. 2008;98:539–40.
Kim KH, Sung MW, Roh JL, Han MH. Sclerotherapy for congenital lesions in the head and neck. Otolaryngol Head Neck Surg. 2004;131:307–16.
Sung MW, Chang SO, Choi JH, Kim JY. Bleomycin sclerotherapy in patients with congenital lymphatic malformation in the head and neck. Am J Otolaryngol. 1995;16:236–41.
Yamamoto T. Bleomycin and the skin. Br J Dermatol. 2006;155:869–75.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Ethical statement
The Institutional Review Board approved the study.
About this article
Cite this article
Yılmaz, H., Yılmaz, Ö., Çamlıdağ, İ. et al. Single center experience with intralesional bleomycin sclerotherapy for lymphatic malformations. Jpn J Radiol 35, 590–596 (2017). https://doi.org/10.1007/s11604-017-0672-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11604-017-0672-5